Veracyte, Inc 8-K, filed Nov 4, 2026

Veracyte, Inc. (VCYT)

8-K 2026-11-04 For: 2026-11-04

Added on November 04, 2026

About this 8-K

Veracyte, Inc filed this 8-K on November 4, 2026.

Veracyte reported third-quarter revenue of $151.8 million, up 15%, GAAP net income of $31.5 million and adjusted EBITDA of $41.2 million for the period ended September 30, 2026. It launched a $100 million share repurchase program and expects 2026 revenue of $590 million to $593 million. AI summary

Items reported

Item 2.02: Financial results
Item 8.01: Other events
Item 9.01: Financial statements and exhibits

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


6000 Shoreline Court, Suite 300, South San Francisco, California						94080
(Address of principal executive offices)						(Zip Code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Exhibit No.						Description

99.1						Press release issued by Veracyte, Inc. dated November 4 , 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).


Dated:	November 4, 2026

		VERACYTE, INC.

		By:	/s/ Rebecca Chambers
		Name:	Rebecca Chambers
		Title:	Chief Financial Officer
			Principal Financial Officer


VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Revenue:
Testing revenue	$	146,419	$	127,756	$	427,171	$	357,328
Product revenue	4,626		3,301		12,163		10,479
Biopharmaceutical and other revenue	709		815		1,812		8,702
Total revenue	151,754		131,872		441,146		376,509

Cost of revenue: (1)
Cost of testing revenue	38,477		33,777		108,092		94,444
Cost of product revenue	2,766		3,015		7,172		6,186
Cost of biopharmaceutical and other revenue	142		1,091		357		7,361
Intangible asset amortization - cost of revenue	3,265		2,707		8,713		7,959
Total cost of revenue	44,650		40,590		124,334		115,950
Gross profit	107,104		91,282		316,812		260,559
Operating expenses: (1)
Research and development	32,159		15,981		88,699		49,965
Selling and marketing	28,652		24,455		84,071		74,225
General and administrative	29,302		27,278		80,425		93,417
Impairment of assets	—		—		—		20,505
Intangible asset amortization - operating expenses	422		622		1,422		1,865
Total operating expenses	90,535		68,336		254,617		239,977
Income from operations	16,569		22,946		62,195		20,582
Other income (loss), net	4,553		(4,057)		15,424		6,985
Income before income taxes	21,122		18,889		77,619		27,567
Income tax provision (benefit)	(10,381)		(248)		(8,081)		2,363
Net income	$	31,503	$	19,137	$	85,700	$	25,204
Earnings per share:
Basic	$	0.39	$	0.24	$	1.07	$	0.32
Diluted	$	0.38	$	0.24	$	1.04	$	0.32
Shares used to compute earnings per common share:
Basic	80,500,406		78,725,139		80,006,663		78,384,184
Diluted	82,783,915		79,691,703		82,204,307		79,946,386


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited)
(In thousands)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Net income	$	31,503	$	19,137	$	85,700	$	25,204
Other comprehensive income (loss):
Change in currency translation adjustments	(122)		(4,556)		151		19,575
Release of accumulated translation adjustment	—		8,295		—		8,295
Other comprehensive income (loss)	(122)		3,739		151		27,870
Net comprehensive income	$	31,381	$	22,876	$	85,851	$	53,074


VERACYTE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

	September 30,		December 31,
	2026		2025
	(Unaudited)		(See Note 1)
Assets
Current assets:
Cash and cash equivalents	$	199,828	$	362,578
Short-term investments	170,704		50,311
Accounts receivable	56,788		44,660
Supplies	25,818		20,546
Prepaid expenses and other current assets	14,740		10,281
Total current assets	467,878		488,376
Property, plant and equipment, net	24,870		22,192
Right-of-use assets, operating leases	35,097		36,599
Intangible assets, net	184,883		89,148
Goodwill	855,575		767,154
Restricted cash	1,646		1,648
Other assets	3,307		902
Total assets	$	1,573,256	$	1,406,019
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	9,710	$	4,593
Accrued liabilities	60,087		48,801

Current portion of deferred revenue	864		1,160
Current portion of acquisition-related contingent consideration	6,734		1,332
Current portion of operating lease liabilities	6,814		4,051

Total current liabilities	84,209		59,937

Deferred tax liabilities	1,616		646
Acquisition-related contingent consideration, net of current portion	17,245		257
Operating lease liabilities, net of current portion	33,922		35,603
Other liabilities	3,000		—
Total liabilities	139,992		96,443
Total stockholders’ equity	1,433,264		1,309,576
Total liabilities and stockholders’ equity	$	1,573,256	$	1,406,019

1. The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026.


VERACYTE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

	Nine Months Ended September 30,
	2026		2025
Operating activities
Net income	$	85,700	$	25,204
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,247		16,117
Loss on disposal of property, plant and equipment	367		15
Stock-based compensation	40,806		32,700
Deferred income taxes	(11,599)		(13)
Noncash lease expense	2,088		2,289
Revaluation of acquisition-related contingent consideration	(1,110)		(2,713)
Effect of foreign currency on operations	(23)		(3,845)
Amortization of discount on short-term investments	(2,380)		(2,619)
Impairment loss	—		20,505
Non-cash loss on deconsolidation of subsidiary	—		3,863
Changes in operating assets and liabilities:
Accounts receivable	(11,963)		(3,858)
Supplies	(3,435)		(2,642)
Prepaid expenses and other current assets	(4,112)		(6,416)
Other assets	(771)		331
Operating lease liabilities	496		(1,681)
Accounts payable	5,522		(547)
Accrued liabilities and deferred revenue	5,466		7,034
Net cash provided by operating activities	121,299		83,724
Investing activities
Business acquisitions, net of cash acquired	(153,190)		—

Purchase of short-term investments	(234,997)		(99,998)

Proceeds from maturity of short-term investments	116,984		102,116
Issuance of loan receivable	(1,622)		—
Purchases of property, plant and equipment	(8,155)		(5,897)
Net cash used in investing activities	(280,980)		(3,779)
Financing activities
Payment of taxes on vested restricted stock units	(17,462)		(14,645)
Proceeds from the exercise of common stock options and employee stock purchases	14,493		10,572
Net cash used in financing activities	(2,969)		(4,073)
(Decrease) increase in cash, cash equivalents and restricted cash	(162,650)		75,872
Effect of foreign currency on cash, cash equivalents and restricted cash	(102)		707
Net (decrease) increase in cash, cash equivalents and restricted cash	(162,752)		76,579
Cash, cash equivalents and restricted cash at beginning of period	364,226		240,631
Cash, cash equivalents and restricted cash at end of period	$	201,474	$	317,210


VERACYTE, INC.
RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES
(Unaudited)
(In thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Reconciliation of Non-GAAP Cost of Revenue:
GAAP cost of testing revenue	$	38,477		$	33,777		$	108,092		$	94,444
Stock-based compensation expense	(994)			(555)			(3,052)			(1,543)
Acquisition related expenses (1)	(131)			—			(131)			—
Other adjustments (2)	(316)			—			(954)			—
Non-GAAP cost of testing revenue	$	37,036		$	33,222		$	103,955		$	92,901

GAAP cost of product revenue	2,766			3,015			7,172			6,186
Stock-based compensation expense	(1)			—			(2)			(2)
Acquisition related expenses (1)	—			—			—			—
Other adjustments (2)	—			(1,418)			11			(1,450)
Non-GAAP cost of product revenue	$	2,765		$	1,597		$	7,181		$	4,734

GAAP cost of biopharmaceutical and other revenue	142			1,091			357			7,361
Stock-based compensation expense	—			15			—			(123)
Acquisition related expenses (1)	—			—			—			—
Other adjustments (2)	—			—			—			—
Non-GAAP cost of biopharmaceutical and other revenue	$	142		$	1,106		$	357		$	7,238

Reconciliation of Non-GAAP Gross Margin:
GAAP Gross Profit	$	107,104		$	91,282		$	316,812		$	260,559
GAAP Gross Margin	70.6		%	69.2		%	71.8		%	69.2		%
Amortization of intangible assets	3,265			2,707			8,713			7,959
Stock-based compensation expense	995			540			3,054			1,668
Acquisition related expenses (1)	131			—			131			—
Other adjustments (2)	316			1,418			943			1,450
Non-GAAP Gross Profit	$	111,811		$	95,947		$	329,653		$	271,636
Non-GAAP Gross Margin	73.7		%	72.8		%	74.7		%	72.1		%

1.Includes transaction-related expenses. For the three months and nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with acquisition activities ($0.1M).
2.For the three months ended September 30, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3 million). For the three months ended September 30, 2025, adjustments include expenses related to Veracyte SAS investment review. For the nine months ended September 30, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.9 million), partially offset by expense related to the restructuring of Veracyte SAS. For the nine months ended September 30, 2025, adjustments include expenses related to Veracyte SAS investment review.